CN101190277B - 地蟞活血化瘀祛风湿酒的制备方法 - Google Patents
地蟞活血化瘀祛风湿酒的制备方法 Download PDFInfo
- Publication number
- CN101190277B CN101190277B CN2006100703712A CN200610070371A CN101190277B CN 101190277 B CN101190277 B CN 101190277B CN 2006100703712 A CN2006100703712 A CN 2006100703712A CN 200610070371 A CN200610070371 A CN 200610070371A CN 101190277 B CN101190277 B CN 101190277B
- Authority
- CN
- China
- Prior art keywords
- wine
- parts
- weight
- preparation
- blood circulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008280 blood Substances 0.000 title claims abstract description 26
- 210000004369 blood Anatomy 0.000 title claims abstract description 25
- 230000017531 blood circulation Effects 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 230000003213 activating effect Effects 0.000 title abstract 2
- 239000000843 powder Substances 0.000 claims abstract description 25
- 108010010803 Gelatin Proteins 0.000 claims abstract description 11
- 229920000159 gelatin Polymers 0.000 claims abstract description 11
- 239000008273 gelatin Substances 0.000 claims abstract description 11
- 235000019322 gelatine Nutrition 0.000 claims abstract description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 11
- 238000001556 precipitation Methods 0.000 claims abstract description 11
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 5
- 240000006432 Carica papaya Species 0.000 claims abstract 2
- 235000009467 Carica papaya Nutrition 0.000 claims abstract 2
- 241000208688 Eucommia Species 0.000 claims abstract 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims description 31
- 230000001737 promoting effect Effects 0.000 claims description 13
- 239000012567 medical material Substances 0.000 claims description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 239000001506 calcium phosphate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 7
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 7
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 240000000031 Achyranthes bidentata Species 0.000 claims description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 4
- 239000004927 clay Substances 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 1
- 241000361919 Metaphire sieboldi Species 0.000 claims 1
- 230000005251 gamma ray Effects 0.000 claims 1
- 229940010454 licorice Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002994 raw material Substances 0.000 abstract description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 2
- 238000011049 filling Methods 0.000 abstract description 2
- 241000131329 Carabidae Species 0.000 abstract 2
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 238000009792 diffusion process Methods 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 230000003203 everyday effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000000034 method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000008035 Back Pain Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 208000008930 Low Back Pain Diseases 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000011194 food seasoning agent Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000000247 postprecipitation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 4
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000004856 capillary permeability Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 230000037040 pain threshold Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000270666 Testudines Species 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241001278898 Glycyrrhiza inflata Species 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZBZFFMBWUCAHIW-UHFFFAOYSA-L disodium propan-2-one sulfate Chemical compound [Na+].[Na+].CC(C)=O.[O-]S([O-])(=O)=O ZBZFFMBWUCAHIW-UHFFFAOYSA-L 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 210000000627 locus coeruleus Anatomy 0.000 description 2
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 229960002666 1-octacosanol Drugs 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000217381 Anodonta Species 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 241001148495 Cibotium barometz Species 0.000 description 1
- 241000744472 Cinna Species 0.000 description 1
- 241000382829 Cristaria <bivalve> Species 0.000 description 1
- 241000514824 Cyathula officinalis Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000380130 Ehrharta erecta Species 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 241001489980 Eupolyphaga sinensis Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 description 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 241001180873 Saposhnikovia divaricata Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供一种地鳖活血化瘀祛风湿酒的制备方法,该方法包括以下重量份配比的原料和步骤:a.将3-40的地鳖、5-20的怀牛膝、3-16的防风、3-16的甘草、3-16的桂枝、5-20的白芍、5-20的木瓜、5-20的狗脊、5-20的杜仲粉碎成粗末;b.先加入药材粗末量的0-0.5%的明胶,再加入20-30倍药材粗末量酒体积浓度5-75%的食用酒,常温常压下浸提1-4次,每次1-7天,然后静置0.5-2天除沉淀;c.除去沉淀后的酒液经调味后加入沉淀剂,再经搅拌、精滤,最后灌装、灭菌得产品。该产品澄明,久置无沉淀,祛风湿效果好。
Description
技术领域:
本发明涉及食品领域,更具体的讲涉及一种地蟞活血化瘀祛风湿酒的制备方法。
技术背景:
地蟞咸寒、入心、肝、脾经。其功能主治为:逐瘀,破积,通络,理伤。治包块、肿块和肿瘤积聚,血滞经闭,产后瘀血腹痛,跌打损伤。在《本经》、《药性论》、《纲目》、《本草衍义》、《本草通云》等均有记载。
近年来人们对地蟞虫油脂、氨基酸、蛋白质、维生素,无机盐等的种类及含量进行了研究。地蟞虫基本无毒,可食,是一种营养丰富的昆虫食品。进一步研究表明,地蟞虫含有目前世界上认为抗疲劳效果最好的二十八烷醇。具有益于心血管系统的Se、β-谷甾醇,不饱和脂肪酸(如油酸、亚油酸、棕榈酸,其中油酸含量占油脂中75-86%)等。具有调节血压,促进新陈代谢,延缓动脉粥样硬化的形成,有抗凝血作用,实验显示还具有良好的溶栓作用。有抗氧作用,实验表明地蟞虫可提高心肌和脑对缺血的耐受力。有抗自由基作用:60例冠心病血瘀症患者服用地蟞粉4周血中过氧化脂质明显下降,还原型谷胱甘肽明显上升。另外,地蟞虫还有抗突变作用,为抗肿瘤作用提供了实验数据。
随着医疗卫生事业的发展,人民生活水平的提高,地蟞虫因国内外需求量愈来愈大,在人工饲养技术难题突破以后,人工大棚地窖式饲养地蟞虫是一项成本低,收效快,饲料来源广,消耗少,饲养方法简便的家庭副业,一个辅助劳动力年收入在0.5-3万元不等。在我国的许多地方形成了公司加农户的模式,使广大农户养殖和工厂化利用相结合,开始走向饲养生产、应用研究、加工、销售之路。
而地蟞虫在药物、食品、保健品等方面的应用越来越广。在地蟞养殖户、地蟞养殖区,一些食用地蟞的人逐渐感觉到了地蟞在活血,接骨、壮身等方面的作用,尤其地蟞在活血祛风湿方面的效果,更为独特。在我国,以中药为基本原料制成的治疗风湿的保健酒种类繁多。但尚未见地蟞为主要原料生产的祛风湿的保健制剂。这一产品的开发不仅造福于风湿病人,也有利于地蟞的综合利用,推动地蟞养殖户和相关公司的经济发展。
发明内容:
本发明的目的是提供依据地蟞虫的药用价值和地蟞虫开发利用的需要和现有技术的不足,本发明以地蟞虫为原料开发生产活血化瘀治风湿的保健酒地蟞活血化瘀祛风湿酒的制备方法。
本发明的目的可通过以下技术措施来实现:
该方法包括以下重量份配比的原料和步骤:
a.将3-40的地蟞、5-20的怀牛膝、3-16的防风、3-16的甘草、3-16的桂枝、5-20的白芍、5-20的木瓜、5-20的狗脊、5-20的杜仲粉碎成粗末;
b.先加入药材粗末量的0-0.5%的明胶,再加入20-30倍药材粗末量酒体积浓度5-75%的食用酒,常温常压下浸提1-4次,每次1-7天,然后静置0.5-2天除沉淀;
c.除去沉淀后的酒液经调味后加入沉淀剂,再经搅拌、精滤,最后灌装、灭菌得产品。
本发明的目的还可通过以下技术措施来实现:
上述b工序中的酒体积浓度为5-45%时,明胶的加入量选自0.1-0.5%;所述的沉淀剂选自浸提用酒量的0.3-0.8%的磷酸三钙和0.3-0.8%的活性白土;所述的沉淀剂在酒体积浓度为5-45%时,还包括0.3-0.8%的活性炭和0.1-0.4%硅藻土;所述的搅拌转速为80-250r/min,搅拌时间为0.5-2小时;所述的精滤选用0.1-0.3MPa下的板框过滤机过滤;当酒体积浓度<20%时,选用γ-射线照射灭菌。
1、浸泡药材的酒液浓度可以是任何浓度,一般控制酒体积浓度为5-75%,高浓度酒的浸泡液有效成分含量高,鞣质极少;低浓度酒浸泡液有效成份少,鞣质等杂质多,泡药材的酒液浓度在45-75之间时不必加明胶沉鞣质。
2、如所制酒浓度在20%以下,需进行灌瓶后灭菌处理。
3、药物用高浓度酒浸泡,泡液经沉淀过滤,产品酒液保持澄明。但如果用高浓度酒浸泡液兑成低浓度的酒浸泡液,需要在活性白土和磷酸钙沉淀剂中再加粉末活性炭和硅藻土,然后搅拌过滤,可得澄明液。或者将已沉淀过滤的高浓度酒兑成低浓度酒,酒液变浑浊。需要再向勾兑的浑浊酒液中加入粉末活性炭和硅藻土,然后搅拌过滤可得澄明酒液。
桂枝:为樟科常绿乔木肉桂Cinna momu cassia Presl的嫩枝。
防风:为伞形科多年草本植物防风Saposhnikovia divaricata(Turez.)Schischk.的根。
木瓜:为蔷薇科落叶灌木贴梗海棠Chaenomeles
speciosa(Sweet)Nakai和木瓜C。sinensis(Thouin)Koehne的成熟果实。
狗脊:为蚌壳蕨类多年生草本植物金毛狗脊Cibotium barometz(L.)J.Sm.的根状茎。
地蟞虫:为蟞蠊科昆虫地蟞Eupolyphaga sinensis Walker或冀地蟞Steleophaga plancyi(Boleny)雌虫的全体。
怀牛膝:为苋科多年生草木植物的牛膝(怀牛膝)Achyranthes bidentata BL.和川牛膝Cyathula officinalis Kuan的根。
甘草:为豆科多年草本植物甘草Glycyrrhiza uralensis Fisch或胀果甘草Glycyrrhiza inflata Bat.或光果甘草Glycyrrhiza glabra L的根及根茎。
白芍:为毛莨科多年草本植物芍药Paeonia lactiflora Pall的根。
杜仲:为杜仲科落叶乔木植物杜仲Eucommia ulmoides 0liv.的树皮
功能主治:
活血化瘀,祛邪通络,缓急止痛,用于一切经络痹阻,气血运行不畅所致的肌肉、筋骨、关节发生的疼痛、瘦搐、麻木、屈伸不利。
蟞虫味咸,性辛寒,善长活血化瘀,通络,镇痛,凡气血凝聚之处皆能开之,固有“去血积,搜剔极固”之说。直达病所。为本方之君药。木瓜味酸,酸能入肝,故益筋与血,病腰肾脚膝无力,皆不可缺也;怀牛膝乃足厥阴,少阴之药,善补肝肾,强筋骨,利关节,所主要之病大抵得酒则能补肝肾,又有走而能补之功;杜仲肝经气分药,能使筋骨相着,又有镇痛之功效,本药与木瓜、怀牛膝一起共为本方之臣药。桂枝和营、通阳,祛寒止痛;白芍苦酸,养血敛阳,柔肝止痛;防风味辛,祛风解表,胜湿解痉与桂枝、白芍共为佐药。甘草一则通经络,利关节,二则调和诸药为使药。综观全方活血化瘀,祛邪通络,缓急止痛,共达血和而营卫通畅,经脉调匀之功效。
2、本发明的方法制成的酒对小鼠的镇痛作用。
取18-22g雌性昆明系小鼠,每次1只,放在55±0.5℃的水浴的热板上,至小鼠出现添足所需时间(秒)作为该鼠的痛阈值。该值小于5秒或大于30秒者或跳跃者弃之不用,用该方法选取的合格的小鼠随机分2组。重复测其正常痛阈值,取两次正常痛阈平均值,作为该鼠给药前痛阈值。2组动物分别为生理盐水组,祛风湿酒组,均经口给予,给药15分钟后开始测小鼠痛阈值,如小鼠在60秒钟仍不反应,取下小鼠以免烫伤,其痛阈按60秒钟算,结果见下表:
地蟞祛风湿酒对小鼠镇痛作用(X±SD)
实验结果表明生理盐水组和地蟞祛风湿酒组分别与给药前比较,生理盐水组无明显差异,地蟞祛风湿酒组差异明显,表明该酒有明显的镇痛作用。
2、本发明的方法制成的酒对二甲苯所致的小鼠皮肤毛细血管通透性增高的影响。采用昆明系小鼠(体重18-22g)雌雄各半,随机分成两组,生理盐水组和祛风湿酒组,均经口给予。
给药15分钟后,于尾静脉注入0.5%伊文思蓝生理盐水溶液0.1ml/10g体重。随即于小鼠腹部正中部位去毛皮肤上滴二甲苯0.03ml/只,20分钟后小鼠脱颈椎致死。剥下腹部皮肤根据各兰斑色泽深浅将其分为7-10个级别,1个级别记1分。将每块皮肤蓝斑用手术剪剪碎投入塞玻璃试管内,倒入丙酮-硫酸钠提取液10ml,置暗处放置,每日轻轻摇动该试管2-3次,3日后2000rpm离心10分钟,取上清液于590nm处比色测定光密度,以未泡皮肤之丙酮-硫酸钠液校零。其实验结果见下表。
该酒对二甲苯所致小鼠皮肤毛细血管通透性增高的影响
药物 | 剂量(ml/kg) | 鼠数(只) | 蓝斑色泽深浅(级) | 兰斑染料量ug |
生理盐水 | 2 | 15 | 5.9±1.4 | 2.0±0.3 |
该制剂 | 2 | 15 | 3.0±0.8** | 1.3±0.4** |
将二甲苯滴于小鼠腹部去毛皮肤,因其局部刺激作用导致毛细血管通透性亢进。当于静脉内注入伊文思兰后,伊文思兰即要以从亢进的毛细血管内的血管外渗出,于滴二甲苯的部位形成兰色斑块,染料渗出量的多少可作为判断药物是否能抑制炎症早期毛细血管通透性亢进的指标。
本实验结果说明,不论是皮肤兰斑色泽深浅评分比较,或是以提取染料分光光度结果进行比较,本酒的实验数值明显低于生理盐水对照组,表明该酒能明显抑制二甲苯所致小鼠腹部皮肤毛细血管通透性亢进。
本发明的方法制成的酒的应用效果:
选取腰痛、腿痛膝关节等疼痛的患者共28人,饮用30%祛风湿酒。其中,40-49岁患者3人,全为女性,膝关节痛和腿痛,可饮少量酒。每天饮用100ml,分二次或一次饮完,饮后疼痛症状明显减轻,尤其晚上饮后,立即休息效果最好。
50-59岁女性8人,其中腰痛3人,每人每天饮100ml该酒;膝关节和腿痛4人,每人每天可饮200ml该酒。肩关节痛1人(女),每天饮100ml;饮后立即感觉病情减轻,其中腰痛和肩关节痛患者各1人饮后仍有些痛。
60-69岁患者13人,腰痛患者7人均为男性,膝关节、肘关节、肩关节和踝关节及脚痛患者6人,每天饮100或200ml,其中一腰痛极甚患者饮后减轻不明显,其他饮后疼痛迅速而明显。
70-79岁患者4人,均为男性,四肢痛、麻、屈伸不利,每天饮200ml,四肢痛疼明显减轻,可伸屈。
经对该酒的初步试用,一般饮用量以每天100-200ml为宜,可1次或多次饮下。该酒对患者的疼痛症状,在饮用后有明显减轻。
具体实施方式:
实施例1:
将40g的地蟞、5g怀牛膝、16g防风、3g的甘草、16g的桂枝、5g的白芍、20g的木瓜、5g的狗脊、20g的杜仲粉碎成粗末,加入药材粗末重量的0.5%的明胶,再加入30倍药材粗末量酒体积浓度为5%的食用酒,常温常压下浸提1次,时间为7天,每天拌翻2次,然后静置2天,除去底部沉淀;向经浸提后的药渣中加入自来水浸泡0.5小时,弃渣,液体过滤,代替水作为下次新药浸泡酒的勾兑液,再向经去沉淀后的酒液中加入酒液体积2%的蔗糖、3%的蜂密、1%的酒香精进行调味,然后再加入酒液体积的0.3%(W/V)的磷酸三钙和0.8%的活性白土,0.3%的活性炭,0.4%的硅藻土,以转速为80r/min搅拌2小时,用0.1MPa下的板框过滤机过滤,罐装,用γ-射线照射灭菌得酒体积浓度为5%的澄明酒液。
实施例2:
将3g的地蟞、20g怀牛膝、3g防风、16g的甘草、3g的桂枝、20g的白芍、5g的木瓜、20g的狗脊、5g的杜仲粉碎成粗末,加入药材粗末重量的0.5%的明胶,再加入20倍药材粗末量酒体积浓度为45%的食用酒,常温常压下浸提4次,时间为1天,每天拌翻4次,然后静置0.5天,除去底部沉淀;向经浸提后的药渣中加入自来水浸泡3小时,弃渣,液体过滤,代替水作为下次新药浸泡酒的勾兑液,再向经去沉淀后的酒液中加入酒液体积3%的蔗糖、1%的蜂蜜、1.5%的酒香精进行调味,然后再加入酒液体积的0.8%(W/V)的磷酸三钙和0.3%的活性白土,0.8%的活性炭,0.1%的硅藻土,以转速为250r/min搅拌0.5小时,用0.3MPa下的板框过滤机过滤,罐装得酒体积浓度为45%的澄明酒液。
实施例3:
将20g的地蟞、10g怀牛膝、10g防风、10g的甘草、10g的桂枝、10g的白芍、10g的木瓜、10g的狗脊、10g的杜仲粉碎成粗末,加入药材粗末重量的0.3%的明胶,再加入25倍药材粗末量酒体积浓度为25%的食用酒,常温常压下浸提3次,时间为4天,每天拌翻3次,然后静置1.5天,除去底部沉淀;向经浸提后的药渣中加入自来水浸泡1.5小时,弃渣,液体过滤,代替水作为下次新药浸泡酒的勾兑液,再向经去沉淀后的酒液中加入酒液体积2.5%的蔗糖、2%的蜂蜜、1.2%的酒香精进行调味,然后再加入酒液体积的0.6%(W/V)的磷酸三钙和0.6%的活性白土,0.5%的活性炭,0.3%的硅藻土,以转速为150r/min搅拌1小时,用0.2MPa下的板框过滤机过滤,罐装得酒体积浓度为25%的澄明酒液。
实施例4:
不同的是浸提用食用酒的酒体积浓度为50%,浸提过程中不加入明胶,其他分别同实施例1、2、3。
实施例5:
不同的是浸提用食用酒的酒体积浓度为50%,再向经去沉淀后的酒液中加入酒液体积3.5%的蔗糖和酒香精进行调味,然后只加入磷酸三钙和活性白土,罐装不需要灭菌得产品。其他分别同实施例1、2、3。
实施例6:
不同的是浸提用食用酒的酒体积浓度为75%,其他同实施例5。
Claims (6)
1.地蟞活血化瘀祛风湿酒的制备方法,其特征在于包括以下步骤:
a.将3-40重量份的地蟞、5-20重量份的怀牛膝、3-16重量份的防风、3-16重量份的甘草、3-16重量份的桂枝、5-20重量份的白芍、5-20重量份的木瓜、5-20重量份的狗脊、5-20重量份的杜仲粉碎成粗末;
b.先加入药材粗末量的0.1-0.5%的明胶,再加入20-30倍药材粗末量酒体积浓度5-45%的食用酒,常温常压下浸提1-4次,每次1-7天,然后静置0.5-2天除沉淀;或者向药材粗末中加入20-30倍药材粗末量酒体积浓度50-75%的食用酒,常温常压下浸提1-4次,每次1-7天,然后静置0.5-2天除沉淀;
c.除去沉淀后的酒液经调味后加入沉淀剂,再经搅拌、精滤,最后灌装、灭菌得产品。
2.根据权利要求书1所述的地蟞活血化瘀祛风湿酒的制备方法,其特征在于所述的沉淀剂在酒体积浓度为50-75%和不加入明胶时,沉淀剂选自浸提用酒量的0.3-0.8%的磷酸三钙和0.3-0.8%的活性白土。
3.根据权利要求书1所述的地蟞活血化瘀祛风湿酒的制备方法,其特征在于所述的沉淀剂在酒体积浓度为5-45%和明胶加入量为药材粗末量的0.1-0.5%时,沉淀剂选自浸提用酒量的0.3-0.8%的磷酸三钙和0.3-0.8%的活性白土,还包括0.3-0.8%的活性炭和0.1-0.4%硅藻土。
4.根据权利要求书1所述的地蟞活血化瘀祛风湿酒的制备方法,其特征在于所述的搅拌转速为80-250r/min,搅拌时间为0.5-2小时。
5.根据权利要求书1所述的地蟞活血化瘀祛风湿酒的制备方法,其特征在于所述的精滤选用0.1-0.3MPa下的板框过滤机过滤。
6.根据权利要求书1所述的地蟞活血化瘀祛风湿酒的制备方法,其特征在于当酒体积浓度<20%时,选用γ-射线照射灭菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100703712A CN101190277B (zh) | 2006-11-29 | 2006-11-29 | 地蟞活血化瘀祛风湿酒的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100703712A CN101190277B (zh) | 2006-11-29 | 2006-11-29 | 地蟞活血化瘀祛风湿酒的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101190277A CN101190277A (zh) | 2008-06-04 |
CN101190277B true CN101190277B (zh) | 2011-01-19 |
Family
ID=39485573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100703712A Expired - Fee Related CN101190277B (zh) | 2006-11-29 | 2006-11-29 | 地蟞活血化瘀祛风湿酒的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101190277B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103223062A (zh) * | 2013-04-25 | 2013-07-31 | 苏州谷力生物科技有限公司 | 祛风湿酒及其制备方法 |
CN103937648B (zh) * | 2014-03-24 | 2015-08-19 | 烟台新时代健康产业有限公司 | 一种祛风除湿活血化瘀的保健酒及其制备 |
CN104857402A (zh) * | 2015-05-30 | 2015-08-26 | 孟钧 | 一种治疗强直性脊柱炎的中药组合物 |
CN114224828B (zh) * | 2022-01-17 | 2023-09-26 | 郝翠娟 | 一种治疗骨痛的外用膏剂及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1257715A (zh) * | 1998-12-21 | 2000-06-28 | 任岩东 | 治疗类风湿关节炎的酊剂及其制备方法 |
-
2006
- 2006-11-29 CN CN2006100703712A patent/CN101190277B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1257715A (zh) * | 1998-12-21 | 2000-06-28 | 任岩东 | 治疗类风湿关节炎的酊剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101190277A (zh) | 2008-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103656238A (zh) | 一种治疗风湿骨病的中药组合物 | |
CN102178867A (zh) | 一种益气健脾补肾的中药方剂及其制品 | |
CN103027155A (zh) | 一种桑叶降脂降压保健茶及其制备方法 | |
CN103479909B (zh) | 一种保健酒及其制备工艺 | |
CN102940153A (zh) | 一种改善肉质、蛋质的家禽饲料 | |
CN101190277B (zh) | 地蟞活血化瘀祛风湿酒的制备方法 | |
CN105076582A (zh) | 一种降血压降血脂的原生中草药代用茶及其制备方法 | |
CN101181541A (zh) | 一种排毒健身药酒 | |
CN104958445A (zh) | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 | |
CN108887544A (zh) | 一种天然养生饮料 | |
CN104922299A (zh) | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 | |
CN105733899B (zh) | 一种养生补肾板栗酒及其制备方法 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN112755107A (zh) | 一种治疗阳痿早泄的制剂及其制备方法 | |
CN106107978A (zh) | 一种降血压无名葵保健口服液 | |
CN105998246A (zh) | 一种治疗足跟痛的中药外用膏剂及其制备方法 | |
CN109700889A (zh) | 一种保健眼睛的中药组合物及其制备方法 | |
CN104629998A (zh) | 一种保健养生酒的酿制方法 | |
CN104397282A (zh) | 一种安神补脑的刺五加保健茶及其制备方法 | |
CN1141962C (zh) | 一种治疗银屑病的药 | |
CN103356870B (zh) | 一种治疗产后缺乳的中药制剂及制备方法 | |
CN105920130A (zh) | 治疗足跟痛的中药制备方法及其外用膏剂 | |
CN111575142A (zh) | 一种提高滋阴补虚的功能性石斛酒制备方法 | |
CN104223062B (zh) | 一种降压降糖的地骨皮保健口服液及其制备方法 | |
CN101191110B (zh) | 一种雄地鳖滋阴壮阳酒的制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110119 Termination date: 20111129 |